The Lancet. Infectious diseases Journal

Overview
Identity
View All

publication venue for

Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial. 2024
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.. 23:1119-1129. 2023
Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019.. 22:222-241. 2021
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.. 22:97-109. 2021
Chlorhexidine for skin antisepsis: making the case to keep peripheral venous catheters CLEAN.. 21:902-903. 2021
Implications of insecticide resistance for malaria vector control with long-lasting insecticidal nets: a WHO-coordinated, prospective, international, observational cohort study.. 18:640-649. 2018
Antimicrobial stewardship and public knowledge of antibiotics.. 15:1000-1001. 2015
Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection.. 15:993-995. 2015